Merck raises full-year profit target after cancer drug sales help Q3 beat_老虎社区_美港股上老虎

Merck raises full-year profit target after cancer drug sales help Q3 beat

Reuters2021-10-28

(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

PKsummer
·2021-10-29
Hope your covid19 drug will adapted by whole world then share price rocket to the Mar., [财迷]
回复
点赞
举报
Cyberkien
·2021-10-28
🚀🚀🚀
回复
2
举报
收起
- Felicialim:
  🍇🥥🪨🪨😍
  2021-10-28
  回复
  举报
koolgal
·2021-10-28
Merck would be ending on a high note in view of its raised profit forecast. Nice work Merck!
回复
9
举报
收起
- koolgal:
  Check out my post today on $Health Care Select Sector SPDR Fund(XLV)$
  2021-10-29
  回复
  举报
- koolgal:
  Also you may want to consider $Health Care Select Sector SPDR Fund(XLV)$ which includes Merck. It is cheaper and more diversified.
  2021-10-29
  回复
  举报
- koolgal回复Chihyong:
  Thanks 👍😊
  2021-10-29
  回复
  举报
查看更多 2 条评论
hotwheels
·2021-10-28
Merck and Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.
回复
6
举报
BoonHuat
·2021-10-28
Nice.
回复
4
举报
kdcc
·2021-10-28
Like pls.. Thanks..
回复
4
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-29
  回复
  举报
- kdcc:
  Thanks
  2021-10-28
  回复
  举报
- Dazhu:
  ok
  2021-10-28
  回复
  举报
查看更多 2 条评论
Soe77
·2021-10-28
Ho say liaoz!
回复
3
举报
Valeriechan
·2021-10-28
[Cool]
回复
2
举报
收起
- Valeriechan:
  B
  2021-10-28
  回复
  举报
Tck
·2021-10-28
[龇牙]
回复
3
举报
收起
- Tck:
  g
  2021-10-28
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2178265612?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-28 19:40","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2178265612","market":"us","top_or_hot":-1,"title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","media":"Reuters","content":"<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","article_id":"2178265612","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","pubTimestamp":1635421212,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"抗癌药物销售帮助第三季度战胜默沙东提高全年利润目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9},"content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":854501834,"gmtCreate":1635466095893,"gmtModify":1635466096136,"author":{"id":"3580513309629633","authorId":"3580513309629633","name":"PKsummer","avatar":"https://static.tigerbbs.com/b5f0208af7339a9a99bccadb33f50d22","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580513309629633","authorIdStr":"3580513309629633"},"htmlText":"Hope your covid19 drug will adapted by whole world then share price rocket to the Mar.,&nbsp;[财迷]&nbsp;","listText":"Hope your covid19 drug will adapted by whole world then share price rocket to the Mar.,&nbsp;[财迷]&nbsp;","text":"Hope your covid19 drug will adapted by whole world then share price rocket to the Mar., [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854501834","repostId":2178265612,"repostType":4,"repost":{"id":"2178265612","kind":"news","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck &amp; Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":854370744,"gmtCreate":1635424259477,"gmtModify":1635424594572,"author":{"id":"4087275030265320","authorId":"4087275030265320","name":"Cyberkien","avatar":"https://static.tigerbbs.com/9cf0950785302dba9fc6bb16c8df76ac","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4087275030265320","authorIdStr":"4087275030265320"},"htmlText":"🚀🚀🚀","listText":"🚀🚀🚀","text":"🚀🚀🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854370744","repostId":2178265612,"repostType":4,"repost":{"id":"2178265612","kind":"news","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck &amp; Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6359183,"gmtCreate":1635424915779,"gmtModify":1635424915881,"authorId":3576273819527804,"author":{"id":3576273819527804,"idStr":"3576273819527804","authorId":3576273819527804,"name":"Felicialim","avatar":"https://static.tigerbbs.com/93b9dd65b95fb4d9322224d3c233d6f4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854370744,"type":1,"supId":0,"prevId":0,"content":"🍇🥥🪨🪨😍","text":"🍇🥥🪨🪨😍","html":"🍇🥥🪨🪨😍"}],"langContent":"CN"},{"id":854352831,"gmtCreate":1635422974270,"gmtModify":1635465265519,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"htmlText":"Merck would be ending on a high note in view of its raised profit forecast.&nbsp; Nice work Merck!&nbsp;","listText":"Merck would be ending on a high note in view of its raised profit forecast.&nbsp; Nice work Merck!&nbsp;","text":"Merck would be ending on a high note in view of its raised profit forecast. Nice work Merck!","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":9,"commentSize":10,"repostSize":0,"link":"https://laohu8.com/post/854352831","repostId":2178265612,"repostType":4,"repost":{"id":"2178265612","kind":"news","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck &amp; Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6364075,"gmtCreate":1635465265491,"gmtModify":1635465265491,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854352831,"type":1,"supId":6363375,"prevId":0,"content":"Check out my post today on <a href=\"https://laohu8.com/S/XLV\"> $Health Care Select Sector SPDR Fund(XLV)$ </a>","text":"Check out my post today on <a href=\"https://laohu8.com/S/XLV\"> $Health Care Select Sector SPDR Fund(XLV)$ </a>","html":"Check out my post today on <a href=\"https://laohu8.com/S/XLV\"> $Health Care Select Sector SPDR Fund(XLV)$ </a>"},{"id":6364068,"gmtCreate":1635465241867,"gmtModify":1635465241867,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854352831,"type":1,"supId":6363375,"prevId":0,"content":"Also you may want to consider <a href=\"https://laohu8.com/S/XLV\"> $Health Care Select Sector SPDR Fund(XLV)$ </a>which includes Merck. It is cheaper and more diversified.&nbsp;","text":"Also you may want to consider <a href=\"https://laohu8.com/S/XLV\"> $Health Care Select Sector SPDR Fund(XLV)$ </a>which includes Merck. It is cheaper and more diversified.&nbsp;","html":"Also you may want to consider <a href=\"https://laohu8.com/S/XLV\"> $Health Care Select Sector SPDR Fund(XLV)$ </a>which includes Merck. It is cheaper and more diversified.&nbsp;"},{"id":6364049,"gmtCreate":1635465153922,"gmtModify":1635465153922,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3583038013988308,"repliedAuthor":{"id":3583038013988308,"idStr":"3583038013988308","authorId":3583038013988308,"name":"Chihyong","avatar":"https://static.tigerbbs.com/b8345100cc574b68844750cc9debaa37","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":854352831,"type":1,"supId":6359091,"prevId":6359153,"content":"Thanks 👍😊","text":"Thanks 👍😊","html":"Thanks 👍😊"},{"id":6364047,"gmtCreate":1635465147008,"gmtModify":1635465147008,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854352831,"type":1,"supId":6359091,"prevId":0,"content":"Thanks 👍😊","text":"Thanks 👍😊","html":"Thanks 👍😊"},{"id":6364043,"gmtCreate":1635465137196,"gmtModify":1635465137196,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854352831,"type":1,"supId":6363375,"prevId":0,"content":"Yes but monitor first. 👍😊","text":"Yes but monitor first. 👍😊","html":"Yes but monitor first. 👍😊"}],"langContent":"CN"},{"id":854353726,"gmtCreate":1635422578729,"gmtModify":1635422868012,"author":{"id":"3555967496683005","authorId":"3555967496683005","name":"hotwheels","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3555967496683005","authorIdStr":"3555967496683005"},"htmlText":"Merck and&nbsp;Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.","listText":"Merck and&nbsp;Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.","text":"Merck and Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854353726","repostId":2178265612,"repostType":4,"repost":{"id":"2178265612","kind":"news","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck &amp; Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":854327873,"gmtCreate":1635422134904,"gmtModify":1635422135177,"author":{"id":"3574549633778650","authorId":"3574549633778650","name":"BoonHuat","avatar":"https://static.tigerbbs.com/f64154b666040668c472fc3731becde7","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3574549633778650","authorIdStr":"3574549633778650"},"htmlText":"Nice.","listText":"Nice.","text":"Nice.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854327873","repostId":2178265612,"repostType":4,"repost":{"id":"2178265612","kind":"news","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck &amp; Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":854322524,"gmtCreate":1635421889209,"gmtModify":1635421889477,"author":{"id":"3582248787663478","authorId":"3582248787663478","name":"kdcc","avatar":"https://static.tigerbbs.com/6b7ab80d653c786d04ef593538824fd5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582248787663478","authorIdStr":"3582248787663478"},"htmlText":"Like pls.. Thanks..&nbsp;","listText":"Like pls.. Thanks..&nbsp;","text":"Like pls.. Thanks..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/854322524","repostId":2178265612,"repostType":4,"repost":{"id":"2178265612","kind":"news","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck &amp; Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6363353,"gmtCreate":1635462957206,"gmtModify":1635462957312,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854322524,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":6358741,"gmtCreate":1635422104708,"gmtModify":1635422104737,"authorId":3582248787663478,"author":{"id":3582248787663478,"idStr":"3582248787663478","authorId":3582248787663478,"name":"kdcc","avatar":"https://static.tigerbbs.com/6b7ab80d653c786d04ef593538824fd5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854322524,"type":1,"supId":6358737,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"},{"id":6358737,"gmtCreate":1635422089346,"gmtModify":1635422089384,"authorId":3575197337244742,"author":{"id":3575197337244742,"idStr":"3575197337244742","authorId":3575197337244742,"name":"Dazhu","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854322524,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":6358719,"gmtCreate":1635421995023,"gmtModify":1635421995053,"authorId":3582248787663478,"author":{"id":3582248787663478,"idStr":"3582248787663478","authorId":3582248787663478,"name":"kdcc","avatar":"https://static.tigerbbs.com/6b7ab80d653c786d04ef593538824fd5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854322524,"type":1,"supId":6358707,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"},{"id":6358707,"gmtCreate":1635421940739,"gmtModify":1635421940768,"authorId":3562791266647459,"author":{"id":3562791266647459,"idStr":"3562791266647459","authorId":3562791266647459,"name":"Atsc89","avatar":"https://static.tigerbbs.com/9ec47b1c36e59ba1ef8caac8ab619319","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854322524,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"CN"},{"id":854326061,"gmtCreate":1635421667514,"gmtModify":1635421667628,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4092299591527610","authorIdStr":"4092299591527610"},"htmlText":"Ho say liaoz!","listText":"Ho say liaoz!","text":"Ho say liaoz!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854326061","repostId":2178265612,"repostType":4,"repost":{"id":"2178265612","kind":"news","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck &amp; Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":854328809,"gmtCreate":1635421594838,"gmtModify":1635421595248,"author":{"id":"3583897064119156","authorId":"3583897064119156","name":"Valeriechan","avatar":"https://static.tigerbbs.com/90dcd0f544e6b3d9d7fbe65dbe16a0d3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583897064119156","authorIdStr":"3583897064119156"},"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854328809","repostId":2178265612,"repostType":4,"repost":{"id":"2178265612","kind":"news","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck &amp; Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6358627,"gmtCreate":1635421609798,"gmtModify":1635421609824,"authorId":3583897064119156,"author":{"id":3583897064119156,"idStr":"3583897064119156","authorId":3583897064119156,"name":"Valeriechan","avatar":"https://static.tigerbbs.com/90dcd0f544e6b3d9d7fbe65dbe16a0d3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854328809,"type":1,"supId":0,"prevId":0,"content":"B","text":"B","html":"B"}],"langContent":"CN"},{"id":854321307,"gmtCreate":1635421474476,"gmtModify":1635421529062,"author":{"id":"3583241719564784","authorId":"3583241719564784","name":"Tck","avatar":"https://static.tigerbbs.com/916da960b2815980b6534526bd75788b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583241719564784","authorIdStr":"3583241719564784"},"htmlText":"[龇牙]&nbsp;","listText":"[龇牙]&nbsp;","text":"[龇牙]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854321307","repostId":2178265612,"repostType":4,"repost":{"id":"2178265612","kind":"news","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck &amp; Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6358599,"gmtCreate":1635421495228,"gmtModify":1635421495258,"authorId":3583241719564784,"author":{"id":3583241719564784,"idStr":"3583241719564784","authorId":3583241719564784,"name":"Tck","avatar":"https://static.tigerbbs.com/916da960b2815980b6534526bd75788b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854321307,"type":1,"supId":0,"prevId":0,"content":"<u>g</u>","text":"<u>g</u>","html":"<u>g</u>"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":56,"commentSize":9,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}